paromlimab

Paromlimab (QL1604) is a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. Developed by Qilu Pharmaceutical, it functions as an immune checkpoint inhibitor by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade prevents the down-regulation of T-cell activity, thereby restoring and enhancing the immune system's ability to identify and destroy tumor cells. Paromlimab is being investigated across a range of solid tumors; it has reached Phase 3 development for cervical cancer (with a BLA submitted in China) and is being evaluated in the RADICAL trial for locally advanced rectal adenocarcinoma as part of a neoadjuvant dual immunotherapy regimen alongside the PD-1/CTLA-4 bifunctional antibody tuvonralimab.

Other names

QL-1604QL1604QL 1604anti-PD-1 monoclonal antibody QL1604anti-PD1 monoclonal antibody QL1604anti-PD 1 monoclonal antibody QL1604